menu
    • menu
    [{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CPO107","moa":"CD20\/SIRP-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conjupro Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Conjupro Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"CSPC ZhongQi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CPO-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conjupro Biotherapeutics \/ CSPC ZhongQi","highestDevelopmentStatusID":"6","companyTruncated":"Conjupro Biotherapeutics \/ CSPC ZhongQi"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"CSPC Megalith","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CPO102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conjupro Biotherapeutics \/ CSPC Megalith","highestDevelopmentStatusID":"6","companyTruncated":"Conjupro Biotherapeutics \/ CSPC Megalith"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CPO301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Conjupro Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Conjupro Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"CSPC-NBP Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"n-Butylphthalide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Conjupro Biotherapeutics \/ CSPC-NBP Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Conjupro Biotherapeutics \/ CSPC-NBP Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Conjupro Biotherapeutics

    Menu

    Conjupro Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPO301

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

                            Details : CPO301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : CPO301

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPO102

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CSPC Megalith

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

                            Details : CPO102 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 14, 2021

                            Lead Product(s) : CPO102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CSPC Megalith

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPO-100

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CSPC ZhongQi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

                            Details : CPO-100 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 18, 2021

                            Lead Product(s) : CPO-100

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CSPC ZhongQi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPO107

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma

                            Details : CPO107 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 21, 2021

                            Lead Product(s) : CPO107

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n-Butylphthalide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CSPC-NBP Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

                            Details : N-Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2020

                            Lead Product(s) : n-Butylphthalide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CSPC-NBP Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth